Compound: Anecortave acetate
SMILES: O=C1C=C2[C@](C3=CC[C@@]4([C@@](O)(C(=O)COC(=O)C)CC[C@H]4[C@@H]3CC2)C)(C)CC1
InChIKey: YUWPMEXLKGOSBF-GACAOOTBSA-N
Synonyms: Anecortave acetate, 7753-60-8, AL-3789, Al 3789, 17,21-Dihydroxypregna-4,9(11)-diene-3,20-dione 21-Acetate, NSC-15475, NSC-24345, Y0PC411K4T, DTXSID5046805, AL3789, DTXCID3026805, 4,9(11)-pregnadien-17alpha,21-diol-3,20-dione-21-acetate, 2-[(1R,3aS,3bS,9aS,11aS)-1-hydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate, 2-((1R,3aS,3bS,9aS,11aS)-1-hydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,11H,11aH-cyclopenta(a)phenanthren-1-yl)-2-oxoethyl acetate, RefChem:558056, 231-812-5, Retaane, Anecortave acetate [USAN], Anecortave [INN], 21-(Acetyloxy)-17-hydroxypregna-4,9(11)-diene-3,20-dione, ANECORTAVE ACETATE F0E2980.997MG/MG(AI), 17-Hydroxy-3,20-dioxopregna-4,9(11)-dien-21-yl acetate, [2-[(8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate, Retaane suspension, 2-((8S,10S,13S,14S,17R)-17-Hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate, NSC 15475, NSC 24345, UNII-Y0PC411K4T, anecortave-acetate, NCGC00181018-01, 2-[(8S,10S,13S,14S,17R)-17-Hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl Acetate, EINECS 231-812-5, Anecortave acetate/H6, ANECORTAVE [MART.], SCHEMBL94110, 17-Hydroxy-3,20-dioxopregna-4,9(11)-dien-21-yl acetate #, orb1306352, ANECORTAVE ACETATE [MI], Anecortave acetate (JAN/USAN), ANECORTAVE ACETATE [JAN], CHEMBL2106613, CHEBI:31215, EX-A5253, NSC15475, NSC24345, Tox21_112668, 17-alpha,21-Dihydroxypregna-4,9(11)-diene-3,20-dione 21-acetate, EBC-85084, MFCD00921393, AKOS015917580, DB05288, FA17919, DA-50466, SY421327, TS-08155, CAS-7753-60-8, HY-116868, CS-0066714, NS00037926, D01733, G76948, Q4761567, HYDROCORTISONE ACETATE IMPURITY E [EP IMPURITY], 21-acetoxy-17-hydroxy-4,9(11)-pregnadiene-3,20-dione, 17alpha-hydroxy-21-acetoxypregna-4,9(11)-diene-3,20-dione, Pregn-4,9(11)-dien-17,21-diol-3,20-dione, acetate(ester), 17alpha-hydroxy-21 -acetoxy-pregna-4,9(11)-diene-3,20-dione, Pregna-4,9(11)-diene-3,20-dione, 21-(acetyloxy)-17-hydroxy-, [2-[(8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl] acetate
Theoretical properties:
molecular_formula: C23H30O5
molecular_weight: 386.5 g/mol
exact_mass: 386.20932405 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 4
heavy_atom_count: 28
topological_polar_surface_area: 80.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Anecortave acetate is an organic molecular entity.
chembl: ANECORTAVE ACETATE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Anecortave (rINN)  is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although similar in chemical structure to the corticosteroid hydrocortisone acetate, it possesses no glucocorticoid activity. If it is approved, it will be marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane. No development has been reported since 2010.